NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

Health Technology Appraisal

Pemetrexed disodium for the treatment of mesothelioma

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Eli Lilly and Company Ltd	Board of Community Health Councils in
(pemetrexed disodium)	Wales
Deliant/sanan manan	British National Formulary
Patient/carer groups Asbestos Diseases UK	Health and Safety Executive
	National Public Health Service for Welce
British Lung FoundationCancer BACUP	Wales NHS Confederation
Cancer Voices	NHS ConfederationNHS Purchasing and Supplies Agency
June Hancock Mesothelioma	NHS Quality Improvement Scotland
Research Fund	- Ni io Quality improvement occitand
Long Term Medical Conditions	Comparator manufacturers
Alliance	Mayne Pharma plc (cisplatin)
Macmillan Cancer Relief	Bristol-Myers Squibb Pharmaceuticals
Marie Curie Cancer Care	Ltd (cisplatin)
National Cancer Alliance	 Approved Prescription Services Ltd
 National Council for Palliative Care 	(cisplatin)
Occupational and Environmental	Data and an analysis
Diseases Association	Relevant research groups
Ridings Asbestos Support and Assaura (RASAC)	British Thoracic Oncology GroupInstitute of Cancer Research
Awareness Group (RASAG)	MD0 0" 1 1 T 1 1 11 11
 Roy Castle Lung Cancer Foundation Tenovus Cancer Information Centre 	MRC Clinical Trials Unit National Cancer Research Institute
Tenovus Cancer Information Centre	National Cancer Research institute
Professional groups	Assessment team
Association of Cancer Physicians	Liverpool Reviews and Implementation
Association for Palliative Medicine of	Group
Great Britain	National Coordinating Centre for Health
British Mesothelioma Interest Group	Technology Assessment
(BMIG)	
British Oncological Association	Associated Guideline Groups
British Oncology Pharmacy	National Collaborating Centre for Capper
Association	Cancer
British Psychosocial Oncology Society	
Society • British Thoracic Society (Lung Cancer	
British Thoracic Society (Lung Cancer)	

National Institute for Clinical Excellence Consultation on the draft scope for the appraisal of **Pemetrexed disodium for the treatment of mesothelioma**

Issue date: March 2005

and Mesothelioma Working party)

- Cancer Research UK
- National Lung Cancer Forum for Nurses
- Royal College of Nursing
- Royal College of Physicians of Edinburgh
- Royal College of Physicians' Intercollegiate Lung Cancer Group
- Royal College of Physicians' Medical Oncology Joint Special Committee
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Society of Cardiothoracic Surgeons of Great Britain and Ireland
- Society of Radiographers

Others

- Department of Health
- Hartlepool PCT
- North Birmingham PCT
- Welsh Assembly Government

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Clinical Excellence Consultation on the draft scope for the appraisal of **Pemetrexed disodium for the treatment of mesothelioma** Issue date: March 2005

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, the *British National Formulary*, and the British Medical Association.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).